Bupropion Formulations and Initial Selection
Start with bupropion SR (sustained-release) 150 mg once daily in the morning, titrating to 150 mg twice daily after 3 days if tolerated. This formulation offers the best balance of efficacy, tolerability, and dosing flexibility for most patients initiating treatment 1.
Available Formulations
Bupropion comes in three bioequivalent formulations that differ only in dosing frequency 2, 3:
- Immediate-Release (IR): 3 times daily dosing
- Sustained-Release (SR): Twice daily dosing
- Extended-Release (XL): Once daily dosing
All three formulations produce equivalent systemic exposure to bupropion and its active metabolites, meaning they are therapeutically interchangeable 2, 4, 3.
Why Start with SR Formulation
The SR formulation is the optimal starting choice because:
- Titration flexibility: You can start at 150 mg once daily for 3 days, then increase to the therapeutic dose of 150 mg twice daily (300 mg total), allowing patients to adjust to the medication gradually 5, 1
- Proven efficacy: Extensively studied with demonstrated effectiveness equal to SSRIs but with significantly less sexual dysfunction and somnolence 2, 4
- Seizure risk management: The twice-daily dosing keeps individual doses at 150 mg, staying well below the 200 mg single-dose threshold that increases seizure risk 1
When to Consider XL Instead
Switch to XL 150 mg once daily (titrating to 300 mg daily after 4 days) if:
- Patient adherence is a concern with twice-daily dosing
- Patient specifically requests once-daily dosing for convenience
- Patient has successfully tolerated SR and wants to simplify their regimen 6
The XL formulation showed therapeutic equivalence to SR in direct comparison studies, with similar adverse event profiles 6.
Critical Dosing Parameters
Maximum daily dose: 300 mg for SR formulation (150 mg twice daily) 5, 1. The 400 mg/day dose used in some trials showed higher discontinuation rates (11% vs 9% at 300 mg) without proportional benefit 1.
Timing considerations:
- Give morning dose upon awakening
- Second SR dose should be at least 8 hours after first dose
- Never give second dose late in day to minimize insomnia risk 7
Absolute Contraindications
Do not prescribe bupropion if patient has:
- Seizure disorder or seizure risk factors (stroke, brain metastases, eating disorders, abrupt benzodiazepine/alcohol discontinuation) 5, 1
- Current or recent (within 14 days) MAO inhibitor use 7, 8, 1
- Uncontrolled hypertension 7
- Bulimia or anorexia nervosa (4-fold increased seizure risk) 1
Special Clinical Scenarios
Depression with anxiety: Despite historical concerns, bupropion can be used in patients with comorbid anxiety. Recent data show comparable anxiolytic efficacy to SSRIs/SNRIs in mild-to-moderate anxiety, though start at lower doses and monitor closely 9. The 2008 ACP guidelines found no efficacy differences between bupropion and SSRIs for depression treatment 10.
Smoking cessation: If treating both depression and smoking, use the same SR dosing (150 mg once daily for 3 days, then 150 mg twice daily). Initiate 1-2 weeks before quit date 5, 8.
Renal/hepatic impairment:
- Moderate-severe renal impairment: Reduce to 150 mg once daily 11
- Moderate-severe hepatic impairment: Reduce to 150 mg once daily or every other day 7
Monitoring Requirements
Assess patient within 1-2 weeks of initiation for:
- Suicidal ideation (highest risk in first 1-2 months) 10, 1
- Anxiety, agitation, or behavioral changes 1
- Blood pressure (bupropion can increase BP) 7
- Seizure-like symptoms 1
If no adequate response by 6-8 weeks, modify treatment 10. Continue monitoring every 2-4 weeks during titration and stabilization.
Common Pitfalls to Avoid
- Don't combine with other bupropion-containing products (Zyban, Aplenzin, or generic formulations) - this is a common error that increases seizure risk 1
- Don't crush, split, or chew tablets - this destroys the extended-release mechanism and increases seizure risk 1
- Don't abruptly discontinue alcohol or benzodiazepines while on bupropion - this dramatically increases seizure risk 1
- Don't exceed 150 mg per individual dose with SR formulation 1
Treatment Duration
Continue for 4-12 months after first depressive episode. For recurrent depression (≥2 prior episodes), consider indefinite maintenance given 70-90% recurrence risk 11.